| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
9 companies
Healy James is a Director at RAPP, with reported holdings spanning 9 companies. Recent filings cover 32 purchases and 10 sales. Those positions are worth an estimated $123.4M at current prices.
Our model assigns Healy James a below-average insider score of 44/100, based on 10 past trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of -22.1%.
Healy James's largest disclosed position is in RAPP as Director, worth about $72.0M. Net of sales, the recent Form 4 record there shows accumulation of 1,572,336 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2019 | CHRS Coherus Oncology, Inc. | Director | Sell | 360,000 | $22.30 | $8,027,600.00 | -15.7% | |
| Jun 20, 2019 | CHRS Coherus Oncology, Inc. | Director | Sell | 317,130 | $21.37 | $6,777,068.10 | -12.1% | |
| May 22, 2019 | CHRS Coherus Oncology, Inc. | Director | Sell | 257,870 | $20.69 | $5,335,330.30 | -9.0% | |
| Aug 29, 2018 | CHRS Coherus Oncology, Inc. | Director | Sell | 25,000 | $20.50 | $512,500.00 | -0.9% | |
| May 30, 2018 | ITRM Iterum Therapeutics Plc | Director, 10% Owner | Buy | 500,000 | $13.00 | $6,500,000.00 | +40.8% | |
| Mar 11, 2016 | PDSB Pds Biotechnology Corp | Director | Buy | 541,343 | $7.30 | $3,951,641.50 | +23.4% | |
| Oct 6, 2015 | PDSB Pds Biotechnology Corp | Director | Buy | 450,000 | $11.00 | $4,950,000.00 | +24.9% |